111 (ADR)
Connects Chinese consumers and pharmacies through digital pharmacy, online care, and supply-chain services.
Something off on this page? Send us feedback.
Profile
Connects consumers, pharmacies, and healthcare providers in China through a digital-health platform. Its 1 Pharmacy, 1 Clinic, and 1 Medicine businesses pair consumer access and online care with pharmacy supply, while warehouse partnerships reshape fulfillment.
Operates a China-focused digital-health platform linking consumers, pharmacies, and healthcare providers across China through 1 Pharmacy, 1 Clinic, and 1 Medicine.
1 Pharmacy combines consumer access with an offline virtual-pharmacy network; 1 Clinic offers online consultations and electronic prescriptions; and 1 Medicine supplies pharmacies and other healthcare providers. The model connects online and offline pharmacy services through a supply-chain platform.
The operating model is shifting from owned fulfillment operations toward warehouse partnerships, with commissions and marketplace services intended to carry more of the revenue mechanics. The business remains concentrated in China.
Company facts
Key statistics
Year to date +28.6% · Average volume (30d) 4.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026Q1 FY26 | — | −$0.60 | — | — | $342.3M | — | +1.27% |
| Apr 9, 2026Q1 FY26 | — | −$0.20 | — | $599.6M | $403.2M | −32.8% | +2.65% |
| Dec 17, 2025Q3 FY25 | — | −$0.20 | — | $551.2M | $421.5M | −23.5% | +4.26% |
| Sep 17, 2025Q2 FY25 | — | −$0.40 | — | $520.9M | $447.0M | −14.2% | −4.07% |
Financial highlights
| 12 quarters | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $572.5M | $525.1M | $477.0M | $446.5M | $413.8M | $351.4M | |
| Gross profit | $30.1M | $29.0M | $27.6M | $26.5M | $24.2M | $18.7M | |
| Operating income | −$1.1M | $21.6K | $14.1K | −$341.6K | −$690.8K | −$3.0M | |
| Net income | −$3.0M | −$2.6M | −$2.9M | −$1.9M | −$875.1K | −$5.5M | |
| Diluted EPS | −$0.34 | −$0.30 | −$0.33 | −$0.22 | −$0.27 | −$0.62 | |
| Gross margin | 5.3% | 5.5% | 5.8% | 5.9% | 5.8% | 5.3% | |
| Operating margin | -0.2% | 0.0% | 0.0% | -0.1% | -0.2% | -0.8% |
Fiscal years (4-quarter sums)FY21 $1.85B · FY22 $2.01B · FY23 $2.22B · FY24 $2.14B · FY25 $1.86B
Revenue by product · FY25
Balance sheet, Mar 31, 2026Cash & short-term investments $7.9M · Total debt $6.1M · Total assets $41.7M · Shareholders' equity −$15.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 8.74M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Junling Liu · director | 1.45M | 16.65% | Form 4 | Mar 18, 2026 |
| Yu Gang · director | 176.0K | 2.01% | Form 4 | Mar 18, 2026 |
| Renaissance Technologies LLC | 13.0K | 0.15% | 13F | May 14, 2026 |
| Serenus Wealth Advisors, LLC | 4.3K | 0.05% | 13F | Apr 27, 2026 |
| Citigroup Inc | 207 | 0.00% | 13F | May 11, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 15, 2026 | Jian David Sun | director | −58,800 | $0.2300 |
| Jun 15, 2026 | Yang Luke Chen | director | −44,000 | $0.2300 |
| Jun 12, 2026 | Yang Luke Chen | director | −49,920 | $0.2300 |
| Jun 11, 2026 | Jian David Sun | director | −111,100 | $0.2300 |
| Jun 10, 2026 | Jian David Sun | director | −115,440 | $0.2200 |
Peers
Not reported.